|
40 Companies |
|
48 Products |
|
48 Products |
|
0 Mechanisms of Action |
|
20 Trials |
|
419 News |
|
| «12345678» |
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial primary completion date: Sickle Cell Disease Conditioning for Bone Marrow Transplant (clinicaltrials.gov) - Mar 11, 2015
P1, N=24, Suspended, Sponsor: Emory University
Trial primary completion date: Dec 2014 --> Mar 2014
- ||| Trial completion, Enrollment change: Improving Emergency Department Management of Adults With Sickle Cell Disease (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=715, Completed, Sponsor: Duke University
Trial primary completion date: Dec 2014 --> Mar 2014 Enrolling by invitation --> Completed | N=500 --> 715
- Trial completion, Trial primary completion date: Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=88, Completed, Sponsor: St. Jude Children's Research Hospital
Enrolling by invitation --> Completed | N=500 --> 715 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2014
- ||| Trial completion, Enrollment change: The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=77, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2014 Active, not recruiting --> Completed | N=110 --> 77
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed, Enrollment change, Trial primary completion date: Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease (clinicaltrials.gov) - Mar 3, 2015
P2, N=5, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | N=110 --> 77 Recruiting --> Active, not recruiting | N=15 --> 5 | Trial primary completion date: Jul 2013 --> Oct 2014
- morphine sulphate / Generic mfg.
Enrollment change: Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally (clinicaltrials.gov) - Feb 19, 2015
P3, N=40, Active, not recruiting, Sponsor: Children's Healthcare of Atlanta
Recruiting --> Active, not recruiting | N=15 --> 5 | Trial primary completion date: Jul 2013 --> Oct 2014 N=250 --> 40
- | Fragmin (dalteparin sodium) / Pfizer, Eisai
Trial completion: Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo (clinicaltrials.gov) - Feb 19, 2015
P2, N=34, Completed, Sponsor: Duke University
N=250 --> 40 Active, not recruiting --> Completed
- ticagrelor / Generic mfg.
Trial primary completion date: HESTIA 1: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Feb 19, 2015
P2, N=39, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Jan 2016
- || PF-04447943 / Pfizer
PK/PD data, Trial primary completion date: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - Feb 5, 2015
P1, N=64, Recruiting, Sponsor: Pfizer
Trial primary completion date: Sep 2015 --> Jan 2016 Trial primary completion date: May 2015 --> Feb 2016
- simvastatin / Generic mfg.
Trial primary completion date: Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease (clinicaltrials.gov) - Feb 5, 2015
P2, N=25, Recruiting, Sponsor: Children's Hospital & Research Center Oakland
Trial primary completion date: May 2015 --> Feb 2016 Trial primary completion date: Jan 2014 --> May 2015
- hydroxyurea / Generic mfg.
Trial primary completion date, Adherence: Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT (clinicaltrials.gov) - Feb 5, 2015
P2, N=60, Recruiting, Sponsor: Columbia University
Trial primary completion date: Jan 2014 --> May 2015 Trial primary completion date: May 2015 --> Dec 2015
- Enrollment open, Trial primary completion date: Use of Mobile Technology for Intensive Training in Medication Management (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=25, Recruiting, Sponsor: Duke University
Trial primary completion date: May 2015 --> Dec 2015 Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> May 2017
- Enrollment change: Microvessels and Heart Problems in Sickle Cell Disease (clinicaltrials.gov) - Jan 29, 2015
P=N/A, N=65, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> May 2017 N=50 --> 65
- | Trial completion, Trial primary completion date: MAGiC: Magnesium in Crisis (clinicaltrials.gov) - Jan 26, 2015
P2/3, N=208, Completed, Sponsor: Medical College of Wisconsin
N=50 --> 65 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2014
- ||| PF-04447943 / Pfizer
Enrollment open, PK/PD data: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - Jan 12, 2015
P1, N=64, Recruiting, Sponsor: Pfizer
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2014 Not yet recruiting --> Recruiting
- Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial suspension: Safety and Pharmacokinetics of SANGUINATE (clinicaltrials.gov) - Jan 6, 2015
P1, N=15, Suspended, Sponsor: Prolong Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Suspended
- HEOR: Decision Aid for Therapeutic Options In Sickle Cell Disease (clinicaltrials.gov) - Dec 29, 2014
P=N/A, N=120, Recruiting, Sponsor: Emory University
- morphine sulphate / Generic mfg., dextromethorphan / Generic mfg.
Enrollment change, Trial withdrawal: Assessment of Opioid Analgesia in Sickle Cell (clinicaltrials.gov) - Dec 24, 2014
P4, N=0, Withdrawn, Sponsor: Children's Research Institute
Not yet recruiting --> Suspended N=62 --> 0 | Completed --> Withdrawn
- Clinical: The Use of Warmed Saline in Vaso-occlusive Episodes (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=80, Completed, Sponsor: Nationwide Children's Hospital
- Trial completion, Enrollment change: Microvessels and Heart Problems in Sickle Cell Disease (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=50, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
N=62 --> 0 | Completed --> Withdrawn Recruiting --> Completed | N=85 --> 50
- hydroxyurea / Generic mfg.
Trial completion, Trial primary completion date: Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia (clinicaltrials.gov) - Dec 13, 2014
P1, N=39, Completed, Sponsor: Children's Mercy Hospital Kansas City
Recruiting --> Completed | N=85 --> 50 Recruiting --> Completed | Trial primary completion date: Jul 2013 --> Dec 2013
- ||| Oxbryta (voxelotor) / Pfizer
Enrollment open: A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease (clinicaltrials.gov) - Dec 6, 2014
P1, N=128, Recruiting, Sponsor: Global Blood Therapeutics
Recruiting --> Completed | Trial primary completion date: Jul 2013 --> Dec 2013 Not yet recruiting --> Recruiting
- Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion, Trial primary completion date: Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients (clinicaltrials.gov) - Dec 6, 2014
P1, N=24, Completed, Sponsor: Prolong Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Oct 2013 --> Jul 2014
- Trial completion, Enrollment change: Carbon Monoxide Levels and Sickle Cell Disease Severity (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=106, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | Trial primary completion date: Oct 2013 --> Jul 2014 Recruiting --> Completed | N=150 --> 106
- | Inomax (nitric oxide) / Mallinckrodt
Trial completion, Enrollment change: INNOSTAPED: Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children (clinicaltrials.gov) - Dec 5, 2014
P2, N=21, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed | N=150 --> 106 Recruiting --> Completed | N=50 --> 21
- Trial completion, Enrollment change: Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease (clinicaltrials.gov) - Dec 5, 2014
P1, N=5, Completed, Sponsor: Duke University
Recruiting --> Completed | N=50 --> 21 Recruiting --> Completed | N=32 --> 5
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Nov 28, 2014
P2, N=25, Not yet recruiting, Sponsor: Gilead Sciences
- Trial primary completion date: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders (clinicaltrials.gov) - Nov 28, 2014
P1, N=44, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | N=32 --> 5 Trial primary completion date: Apr 2015 --> Apr 2016
- | morphine sulphate / Generic mfg.
Enrollment closed, Trial primary completion date: Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally (clinicaltrials.gov) - Nov 25, 2014
P3, N=250, Active, not recruiting, Sponsor: Children's Healthcare of Atlanta
Trial primary completion date: Apr 2015 --> Apr 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jan 2014
- ||| Enrollment open: PArTNER: PATient Navigator to rEduce Readmissions (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=1130, Recruiting, Sponsor: University of Illinois at Chicago
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jan 2014 Not yet recruiting --> Recruiting
- Enrollment change, Trial termination, Trial primary completion date: Treatment of Sickle Cell Anemia With Stem Cell Transplant (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=2, Terminated, Sponsor: Thomas Jefferson University
Not yet recruiting --> Recruiting N=12 --> 2 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Aug 2011; Poor accrual
- Enrollment closed, Trial primary completion date: Treatment of Sickle Cell Anemia With Stem Cell Transplant (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=12, Active, not recruiting, Sponsor: Thomas Jefferson University
N=12 --> 2 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Aug 2011; Poor accrual Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease (clinicaltrials.gov) - Nov 6, 2014
P2, N=15, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Sep 2014 --> May 2015
- Oxbryta (voxelotor) / Pfizer
New P1 trial: A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease (clinicaltrials.gov) - Nov 6, 2014
P1, N=128, Not yet recruiting, Sponsor: Global Blood Therapeutics
- Trial primary completion date: Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=88, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Sep 2014 --> May 2015 Trial primary completion date: Sep 2014 --> Dec 2014
- || Enrollment closed: The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=110, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Sep 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=6, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting Recruiting --> Completed | N=70 --> 6
- ||| Clinical: Families Taking Control (FTC): Family-based Problem-solving Intervention for Children With Sickle Cell Disease (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=83, Completed, Sponsor: University of Pennsylvania
- ||| Enrollment open: A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=89, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed | N=70 --> 6 Not yet recruiting --> Recruiting
- | hydroxyurea / Generic mfg.
Enrollment open, Trial initiation date: NOHARM: Novel Use Of Hydroxyurea in an African Region With Malaria (clinicaltrials.gov) - Oct 17, 2014
P3, N=200, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Sep 2014
- Enrollment open: MEMREAD: Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=99, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- | ticagrelor / Generic mfg.
Enrollment open, Enrollment change: HESTIA 1: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Sep 28, 2014
P2, N=39, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=49 --> 39
- Enrollment open: Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) - Sep 22, 2014
P2, N=24, Recruiting, Sponsor: Daniel Kim-Shapiro
Not yet recruiting --> Recruiting | N=49 --> 39 Not yet recruiting --> Recruiting
- NKTT120 / NKT Therap
Enrollment closed, Trial primary completion date: Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) (clinicaltrials.gov) - Sep 22, 2014
P1, N=21, Active, not recruiting, Sponsor: NKT Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2014
- Enrollment closed, Trial primary completion date: KNOW-IT: Improving Disease Knowledge in Adolescents With Sickle Cell Disease (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: The University of The West Indies
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Jan 2015
- || Clotinab (abciximab) / Isu Abxis
Trial primary completion date: Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis (clinicaltrials.gov) - Sep 4, 2014
P2, N=100, Recruiting, Sponsor: St. Louis University
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Jan 2015 Trial primary completion date: Nov 2015 --> Mar 2016
- Clinical: Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=99, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- Clinical: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=10, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- | morphine sulphate / Generic mfg., hydromorphone hydrochloride / Generic mfg.
New P4 trial: Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease (clinicaltrials.gov) - Aug 21, 2014
P4, N=77, Not yet recruiting, Sponsor: Duke University
- Trial completion, Enrollment change: Cognitive Rehabilitation in Sickle Cell Disease (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=18, Completed, Sponsor: Duke University
Trial primary completion date: Nov 2015 --> Mar 2016 Recruiting --> Completed | N=30 --> 18